CN108601794A - 调节细胞因子产生 - Google Patents

调节细胞因子产生 Download PDF

Info

Publication number
CN108601794A
CN108601794A CN201680080143.5A CN201680080143A CN108601794A CN 108601794 A CN108601794 A CN 108601794A CN 201680080143 A CN201680080143 A CN 201680080143A CN 108601794 A CN108601794 A CN 108601794A
Authority
CN
China
Prior art keywords
c6orf106
gly
compound
ser
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680080143.5A
Other languages
English (en)
Chinese (zh)
Inventor
C·斯图尔特
R·安布罗斯
A·比恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905035A external-priority patent/AU2015905035A0/en
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of CN108601794A publication Critical patent/CN108601794A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
CN201680080143.5A 2015-12-04 2016-12-02 调节细胞因子产生 Pending CN108601794A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905035A AU2015905035A0 (en) 2015-12-04 Regulation of cytokine production
AU2015905035 2015-12-04
PCT/AU2016/051192 WO2017091866A1 (en) 2015-12-04 2016-12-02 Regulation of cytokine production

Publications (1)

Publication Number Publication Date
CN108601794A true CN108601794A (zh) 2018-09-28

Family

ID=58796001

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680080143.5A Pending CN108601794A (zh) 2015-12-04 2016-12-02 调节细胞因子产生

Country Status (8)

Country Link
US (1) US20180362625A1 (enExample)
EP (1) EP3383408A4 (enExample)
JP (3) JP2019503998A (enExample)
KR (1) KR20180088455A (enExample)
CN (1) CN108601794A (enExample)
AU (2) AU2016363114B2 (enExample)
CA (1) CA3007287A1 (enExample)
WO (1) WO2017091866A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
CN107964564B (zh) * 2017-12-28 2020-09-11 中南大学湘雅医院 胶质瘤诊断标志物circ6:34606555|34606904及应用
KR102805517B1 (ko) * 2022-12-22 2025-05-12 주식회사 셀렉소바이오 강직성 척추염 진단용 조성물, 키트 및 이의 정보제공방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313313A (zh) * 2000-03-10 2001-09-19 上海博德基因开发有限公司 一种新的多肽——人cdc4类似蛋白12和编码这种多肽的多核苷酸
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN101346393A (zh) * 2005-11-02 2009-01-14 普洛体维生物治疗公司 修饰的siRNA分子及其应用
CN101773668A (zh) * 2009-01-09 2010-07-14 中国科学院上海生命科学研究院 一种抗病毒相关蛋白及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
KR101629963B1 (ko) * 2008-07-21 2016-06-14 경희대학교 산학협력단 염증성 질환 진단용 ｃＤＮＡ 마이크로어레이 칩

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313313A (zh) * 2000-03-10 2001-09-19 上海博德基因开发有限公司 一种新的多肽——人cdc4类似蛋白12和编码这种多肽的多核苷酸
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN101346393A (zh) * 2005-11-02 2009-01-14 普洛体维生物治疗公司 修饰的siRNA分子及其应用
CN101773668A (zh) * 2009-01-09 2010-07-14 中国科学院上海生命科学研究院 一种抗病毒相关蛋白及其用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMBROSE RL ET AL: "C6orf106 is a novel inhibitor of the interferon-regulatory factor 3-dependent innate antiviral response", 《J. BIOL. CHEM.》 *
JIANG GY ET AL.: "A novel biomarker C6orf106 promotes the malignant progression of breast cancer", 《TUMOR BIOL.》 *
ROBIC A ET AL: "Expression levels of 25 genes in liver and testis located in a QTL region for androstenone on SSC7q1.2", 《ANIMAL GENETICS》 *
ZHANG XP ET AL.: "C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn", 《TUMOR BIOL.》 *
刘英姿 等: "原花青素A-1调节ConA刺激小鼠脾细胞分泌Th1/Th2细胞因子的影响", 《免疫学杂志》 *

Also Published As

Publication number Publication date
KR20180088455A (ko) 2018-08-03
CA3007287A1 (en) 2017-06-08
AU2016363114A1 (en) 2018-07-05
AU2016363114B2 (en) 2023-04-20
EP3383408A4 (en) 2019-06-26
JP2022028689A (ja) 2022-02-16
EP3383408A1 (en) 2018-10-10
US20180362625A1 (en) 2018-12-20
AU2023204701A1 (en) 2023-09-28
WO2017091866A1 (en) 2017-06-08
JP2024041751A (ja) 2024-03-27
JP2019503998A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
AU2018336126B2 (en) Modifying the specificity of non-coding RNA molecules for silencing gene expression in eukaryotic cells
ES2750550T3 (es) Corrección de gen a base de TALEN
JP2024041751A (ja) サイトカイン産生の調節
KR20210068485A (ko) 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍
KR20220009980A (ko) 조절된 합성 유전자 발현 시스템
US20180010132A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
JP2011529708A (ja) 自然免疫応答の調節因子ｓｔｉｎｇ（インターフェロン遺伝子の刺激因子）
US20190100761A1 (en) Compositions and methods for enhanced gene expression and viral replication
CN108884461A (zh) 在禽蛋中产生病毒
BR112019025358A2 (pt) ovo aviário transgênico, ave transgênica, ovo ou progênie aviária, método para detectar um ovo aviário macho, método para produzir um ovo aviário, método para replicar um vírus, vírus produzidos pelo uso de ovo aviário, método para produzir uma composição de vacina, composição da vacina produzida pelo uso do método e método para produzir um ovo aviário transgênico ou uma ave produzida pelo ovo
US11339209B2 (en) Compositions, methods, and therapeutic uses related to fusogenic protein minion
Linder et al. Defective interfering genomes and the full-length viral genome trigger RIG-I after infection with vesicular stomatitis virus in a replication dependent manner
CN108603188A (zh) 在细胞培养物中产生病毒
CN115698301A (zh) 活性dna转座子系统及其使用方法
Du et al. IFITM3 inhibits severe fever with thrombocytopenia syndrome virus entry and interacts with viral Gc protein
JP7048998B2 (ja) インフルエンザウイルス産生用細胞、及びインフルエンザウイルスの産生方法
CN105586344B (zh) 抑制流感病毒相关基因的siRNA及其应用
KR101354994B1 (ko) 임파구계 혈구계 세포에 유전자 도입을 위한 프로모터 및 그의 이용 방법
US20220133701A1 (en) Methods of treating pain
Min et al. Generation of antiviral transgenic chicken using spermatogonial stem cell transfected in vivo
WO2020198505A1 (en) African elephant polyomavirus constructs and methods of using the same
EP4467563A1 (en) Ldlr derived polypeptides for anti-viral uses
WO2024240848A1 (en) Ldlr derived polypeptides for anti-viral uses
WO2025216732A1 (en) Methods and compositions relating to ecdna biogenesis
HK40088155A (zh) 活性dna转座子系统及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination